副鼻腔炎に対するセアプロ-ゼSの薬効評価-1-Placeboとの二重盲検比較試験成績

概要

論文の詳細を見る
The efficacy of SAP was compared in a double blind study with that of a placebo in patients with chronic sinusitis. The daily dose of SAP was 45mg (3 tablets) and the duration of treatment was 4 weeks. The total number of patients evaluated was 125 in the SAP group and 130 in the placebo group.The results were as follows:1. The SAP group had a significantly better in global utility rating than the placebo group.2. The global improvement rating of the SAP group was significantly better than that of placebo group.3. The SAP group showed greater improvement than the placebo group in respect to postnasal drip and to the decrease in viscosity of nasal secretion.4. X-rays of the sinuses showed definitely improvement of the right maxillary sinus in the SAP group.5. Side-effects were noted in 5.6% of SAP group and in 4.6% of the placebo group, not a significant difference.The results of this study suggest that SAP is a useful drug in the treatment of chronic sinusitis.
耳鼻咽喉科臨床学会の論文